Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [12594]

ASCO 2014: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

ASCO 2014: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

ASCO 2014: Adjuvant ipilimumab improves recurrence-free survival in high-risk melanoma

ASCO 2014: Adjuvant ipilimumab improves recurrence-free survival in high-risk melanoma

ASCO 2014: Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

ASCO 2014: Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in...

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone...

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in...

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast...

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced differentiated thyroid cancer

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced...

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone receptor-negative breast cancer

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone...

More from ecancer